Acute myeloid leukemia stem cell signature gene EMP1 is not an eligible therapeutic target.
Journal
Pediatric research
ISSN: 1530-0447
Titre abrégé: Pediatr Res
Pays: United States
ID NLM: 0100714
Informations de publication
Date de publication:
15 Jun 2024
15 Jun 2024
Historique:
received:
21
02
2024
accepted:
04
06
2024
revised:
17
05
2024
medline:
16
6
2024
pubmed:
16
6
2024
entrez:
15
6
2024
Statut:
aheadofprint
Résumé
Relapse in pediatric acute myeloid leukemia (pedAML) patients is known to be associated with residual leukemic stem cells (LSC). We have previously shown that epithelial membrane protein 1 (EMP1) is significantly overexpressed in LSC compared to hematological stem cell fractions. EMP1 was also documented as part of the 17-gene stemness score and a 6-membrane protein gene score, both correlating high EMP1 expression with worse overall survival. However, its potential as a therapeutic target in pedAML is still unexplored. Association analyses of EMP1 expression with clinical and molecular AML characteristics were performed. Expression of EMP1 was evaluated in pedAML and cord blood samples. Expression in normal blood cells and tissues was evaluated by flow cytometry and immunohistochemistry, respectively. In silico analyses showed variable mRNA expression of EMP1 in multiple pedAML datasets, and a significant correlation between high EMP1 transcript levels and the presence of inv(16). Flow cytometry showed overexpression of EMP1 in pedAML samples, as well as expression in normal blood subsets. Importantly, immunohistochemistry revealed EMP1 expression in multiple normal tissues. Although EMP1 presents as an interesting membrane-associated target in pedAML, its abundant expression in normal blood cells and tissues will impede it from further exploration as a therapeutic target. EMP1 is highly expressed in multiple cancer types, but expression in acute myeloid leukemia (AML) and normal tissues is unexplored. As EMP1 is investigated in other cancer types, expression in normal tissues and blood cells is relevant in predicting the success of EMP1-targeted therapies. In this study, we showed expression of EMP1 in multiple tissues, predicting high on-target off-tumor toxicity, which will warn other researchers of possible toxicities when generating EMP1-targeted therapy. Finally, we showed that high EMP1 expression is associated with better overall survival of pediatric AML patients, reducing the need for EMP1-targeted therapy.
Sections du résumé
BACKGROUND
BACKGROUND
Relapse in pediatric acute myeloid leukemia (pedAML) patients is known to be associated with residual leukemic stem cells (LSC). We have previously shown that epithelial membrane protein 1 (EMP1) is significantly overexpressed in LSC compared to hematological stem cell fractions. EMP1 was also documented as part of the 17-gene stemness score and a 6-membrane protein gene score, both correlating high EMP1 expression with worse overall survival. However, its potential as a therapeutic target in pedAML is still unexplored.
METHODS
METHODS
Association analyses of EMP1 expression with clinical and molecular AML characteristics were performed. Expression of EMP1 was evaluated in pedAML and cord blood samples. Expression in normal blood cells and tissues was evaluated by flow cytometry and immunohistochemistry, respectively.
RESULTS
RESULTS
In silico analyses showed variable mRNA expression of EMP1 in multiple pedAML datasets, and a significant correlation between high EMP1 transcript levels and the presence of inv(16). Flow cytometry showed overexpression of EMP1 in pedAML samples, as well as expression in normal blood subsets. Importantly, immunohistochemistry revealed EMP1 expression in multiple normal tissues.
CONCLUSION
CONCLUSIONS
Although EMP1 presents as an interesting membrane-associated target in pedAML, its abundant expression in normal blood cells and tissues will impede it from further exploration as a therapeutic target.
IMPACT
CONCLUSIONS
EMP1 is highly expressed in multiple cancer types, but expression in acute myeloid leukemia (AML) and normal tissues is unexplored. As EMP1 is investigated in other cancer types, expression in normal tissues and blood cells is relevant in predicting the success of EMP1-targeted therapies. In this study, we showed expression of EMP1 in multiple tissues, predicting high on-target off-tumor toxicity, which will warn other researchers of possible toxicities when generating EMP1-targeted therapy. Finally, we showed that high EMP1 expression is associated with better overall survival of pediatric AML patients, reducing the need for EMP1-targeted therapy.
Identifiants
pubmed: 38879624
doi: 10.1038/s41390-024-03341-x
pii: 10.1038/s41390-024-03341-x
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s), under exclusive licence to the International Pediatric Research Foundation, Inc.
Références
Zwaan, C. M. et al. Collaborative efforts driving progress in pediatric acute myeloid leukemia. J. Clin. Oncol. 33, 2949–2962 (2015).
doi: 10.1200/JCO.2015.62.8289
pubmed: 26304895
pmcid: 4567700
Rasche, M. et al. Successes and challenges in the treatment of pediatric acute myeloid leukemia: a retrospective analysis of the AML-BFM trials from 1987 to 2012. Leukemia 32, 2167–2177 (2018).
doi: 10.1038/s41375-018-0071-7
pubmed: 29550834
pmcid: 6170392
Maloney, K. W. et al. Outcome in children with standard-risk B-cell acute lymphoblastic leukemia: results of children’s oncology group trial AALL0331. J. Clin. Oncol. 38, 602–612 (2020).
doi: 10.1200/JCO.19.01086
pubmed: 31825704
Stelmach, P. & Trumpp, A. Leukemic stem cells and therapy resistance in acute myeloid leukemia. Haematologica 108, 353–366 (2023).
doi: 10.3324/haematol.2022.280800
pubmed: 36722405
pmcid: 9890038
Depreter, B. et al. Deciphering molecular heterogeneity in pediatric AML using a cancer vs. normal transcriptomic approach. Pediatr. Res. 89, 1695–1705 (2021).
doi: 10.1038/s41390-020-01199-3
pubmed: 33069162
Creutzig, U. et al. Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel. Blood 120, 3187–3205 (2012).
doi: 10.1182/blood-2012-03-362608
pubmed: 22879540
Barlogis, V. et al. Late cardiomyopathy in childhood acute myeloid leukemia survivors: a study from the L.E.A. program. Haematologica 100, e186–e189 (2015).
doi: 10.3324/haematol.2014.116574
pubmed: 25616572
pmcid: 4420228
Taylor, V., Welcher, A. A., Program, A. E. & Suter, U. Epithelial membrane protein-1, peripheral myelin protein 22, and lens membrane protein 20 define a novel gene family. J. Biol. Chem. 270, 28824–28833 (1995).
doi: 10.1074/jbc.270.48.28824
pubmed: 7499407
Ng, S. W. K. et al. A 17-gene stemness score for rapid determination of risk in acute leukaemia. Nature 540, 433–437 (2016).
doi: 10.1038/nature20598
pubmed: 27926740
Lin, S.-Y. et al. A 6-membrane protein gene score for prognostic prediction of cytogenetically normal acute myeloid leukemia in multiple cohorts. J. Cancer 11, 251–259 (2020).
doi: 10.7150/jca.35382
pubmed: 31892991
pmcid: 6930412
Lange, B. J. et al. Outcomes in CCG-2961, a children’s oncology group phase 3 Trial for untreated pediatric acute myeloid leukemia: a report from the Children’s Oncology Group. Blood 111, 1044–1053 (2008).
doi: 10.1182/blood-2007-04-084293
pubmed: 18000167
pmcid: 2214754
Gamis, A. S. et al. Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children’s oncology group trial AAML0531. J. Clin. Oncol. 32, 3021–3032 (2014).
doi: 10.1200/JCO.2014.55.3628
pubmed: 25092781
pmcid: 4162498
Pollard, J. A. et al. Sorafenib in combination with standard chemotherapy for children with high allelic ratio FLT3/ITD+ acute myeloid leukemia: a report from the children’s oncology group protocol AAML1031. J. Clin. Oncol. 40, 2023–2035 (2022).
doi: 10.1200/JCO.21.01612
pubmed: 35349331
pmcid: 9197362
Aplenc, R. et al. Bortezomib with standard chemotherapy for children with acute myeloid leukemia does not improve treatment outcomes: a report from the Children’s Oncology Group. Haematologica 105, 1879–1886 (2020).
doi: 10.3324/haematol.2019.220962
pubmed: 32029509
pmcid: 7327649
Balgobind, B. V. et al. Evaluation of gene expression signatures predictive of cytogenetic and molecular subtypes of pediatric acute myeloid leukemia. Haematologica 96, 221–230 (2011).
doi: 10.3324/haematol.2010.029660
pubmed: 20971820
Zhang, N. et al. Unraveling the structures, functions and mechanisms of epithelial membrane protein family in human cancers. Exp. Hematol. Oncol. 11, 69 (2022).
doi: 10.1186/s40164-022-00321-x
pubmed: 36217151
pmcid: 9552464
Ariës, I. M. et al. EMP1, a novel poor prognostic factor in pediatric leukemia regulates prednisolone resistance, cell proliferation, migration and adhesion. Leukemia 28, 1828–1837 (2014).
doi: 10.1038/leu.2014.80
pubmed: 24625531
Wang, J. et al. EMP1 regulates cell proliferation, migration, and stemness in gliomas through PI3K-AKT signaling and CD4. J. Cell. Biochem. 120, 17142–17150 (2019).
doi: 10.1002/jcb.28974
pubmed: 31111534
Hsu, C.-H. et al. Transcriptome profiling of pediatric core binding factor AML. PloS One 10, e0138782 (2015).
doi: 10.1371/journal.pone.0138782
pubmed: 26397705
pmcid: 4580636
Ichikawa, H. et al. Common gene expression signatures in t(8;21)-and inv(16)-acute myeloid leukaemia. Br. J. Haematol. 135, 336–347 (2006).
doi: 10.1111/j.1365-2141.2006.06310.x
pubmed: 16989659